云顶新耀-B(01952)获国药监批准sacituzumab govitecan-hziy用于治疗晚期尿路上皮癌的新药临床试验申请

智通财经2021-01-06

智通财经APP讯，云顶新耀-B(01952)公布，sacituzumab govitecan-hziy日前已获得中国国家药品监督管理局药品审评中心批准，用于开展治疗晚期尿路上皮癌(metastatic urothelial cancer, mUC)的新药临床试验申请。伴随此次新药临床试验申请，作为全球3期TROPiCS-04试验的一部分，该公司计划在中国为这项3期、全球多中心、开放标签、随机...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2101862690?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","is_english":false,"pubTime":"2021-01-06 16:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2101862690","market":"hk","top_or_hot":-1,"title":"云顶新耀-B(01952)获国药监批准sacituzumab govitecan-hziy用于治疗晚期尿路上皮癌的新药临床试验申请","media":"智通财经","content":"<div>\n<p>智通财经APP讯，云顶新耀-B(01952)公布，sacituzumab  govitecan-hziy日前已获得中国国家药品监督管理局药品审评中心批准，用于开展治疗晚期尿路上皮癌(metastatic urothelial  cancer, mUC)的新药临床试验申请。伴随此次新药临床试验申请，作为全球3期TROPiCS-04试验的一部分，该公司计划在中国为这项3期、全球多中心、开放标签、随机...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/389922.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>云顶新耀-B(01952)获国药监批准sacituzumab govitecan-hziy用于治疗晚期尿路上皮癌的新药临床试验申请</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n云顶新耀-B(01952)获国药监批准sacituzumab govitecan-hziy用于治疗晚期尿路上皮癌的新药临床试验申请\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-01-06 16:58 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/389922.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，云顶新耀-B(01952)公布，sacituzumab  govitecan-hziy日前已获得中国国家药品监督管理局药品审评中心批准，用于开展治疗晚期尿路上皮癌(metastatic urothelial  cancer, mUC)的新药临床试验申请。伴随此次新药临床试验申请，作为全球3期TROPiCS-04试验的一部分，该公司计划在中国为这项3期、全球多中心、开放标签、随机...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/389922.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01952","symbol_name":"云顶新耀","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/389922.html","article_id":"2101862690","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2101862690","pubTimestamp":1609923534,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，云顶新耀-B 公布，sacituzumab  govitecan-hziy日前已获得中国国家药品监督管理局药品审评中心批准，用于开展治疗晚期尿路上皮癌的新药临床试验申请。患者将随机入组至  sacituzumab  govitecan-hziy组或者医生选择治疗组。该临床试验旨在对经含铂类药物的化疗和PD-1/PD-L1抗体治疗后仍发生疾病进展的转移性或者局部晚期不可切除的尿路上皮癌患者中对sacituzumab  govitecan-hziy与标准化疗进行评估比较。Sacituzumab  govitecan-hziy该适应症已获得美国食品药品管理局快速通道资格认定。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01952":"云顶新耀","03347":"泰格医药"},"translate_title":"Yunding Xinyao-B (01952) Approved by the State Drug Administration Application for Clinical Trial of Sacituzumab govitecan-hziy as a New Drug for the Treatment of Advanced Urinary Tract Epithelial Cancer","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":1,"03347":1},"content_text":"智通财经APP讯，云顶新耀-B(01952)公布，sacituzumab  govitecan-hziy日前已获得中国国家药品监督管理局药品审评中心批准，用于开展治疗晚期尿路上皮癌(metastatic urothelial  cancer, mUC)的新药临床试验申请。伴随此次新药临床试验申请，作为全球3期TROPiCS-04试验的一部分，该公司计划在中国为这项3期、全球多中心、开放标签、随机临床试验招募患者。患者将随机入组至  sacituzumab  govitecan-hziy组或者医生选择治疗组(包括紫杉醇、多西他赛和长春氟宁)。该临床试验旨在对经含铂类药物的化疗和PD-1/PD-L1抗体治疗后仍发生疾病进展的转移性或者局部晚期不可切除的尿路上皮癌患者中对sacituzumab  govitecan-hziy与标准化疗进行评估比较。此前在113例mUC患者中开展的sacituzumab govitecan-hziy关键性2期TROPHY  U-01研究取得积极结果，并在欧洲肿瘤内科学会(ESMO) 2020年年会上发表，结果证实了较早的研究结果，表明sacituzumab  govitecan-hziy具有显著活性，并且在经过铂类药物化疗和检查点抑制剂(CPI)治疗的mUC患者中是安全的。研究结果显示，对经过多线治疗的mUC患者，  sacituzumab govitecan-hziy达到了27%的总体缓解率(ORR)，中位缓解持续时间(DOR)达5.9个月。Sacituzumab  govitecan-hziy该适应症已获得美国食品药品管理局(FDA)快速通道资格认定。尿道上皮癌是一种始于尿路上皮细胞的癌症类型，尿道上皮细胞位于尿道，与膀胱、输尿管、肾盂和其他器官组成泌尿系统。根据弗若斯特沙利文(Frost&Sullivan)的资料，  2019年中国尿路上皮癌的发病人数达到7.64万。Sacituzumab  govitecan-hziy是一款同类首创的抗体药物偶联物，靶点为TROP-2，其为在许多常见的上皮癌中有过度表达的膜抗原。在与吉利德科学公司签署的授权协议中，该公司拥有在大中华区、韩国和部分东南亚国家就所有癌症适应症对sacituzumab  govitecanhziy进行开发、注册和商业化的独家权益。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2101862690","isCrawlerRequest":true}